Hepatocellular carcinoma with tumor thrombi in the portal vein. A comparison of therapeutic effects by different treatments.
- Author:
Shu-qun CHENG
1
;
Meng-chao WU
;
Han CHEN
;
Feng SHEN
;
Jia-he YANG
;
Wen-ming CONG
;
Yu-xiang ZHAO
;
Pei-jun WANG
;
Guang-hui DING
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; administration & dosage; Carcinoma, Hepatocellular; mortality; surgery; therapy; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Follow-Up Studies; Hepatectomy; methods; Hepatic Artery; Humans; Liver Neoplasms; mortality; surgery; therapy; Male; Middle Aged; Neoplastic Cells, Circulating; pathology; Portal Vein; pathology; Survival Analysis; Thymosin; analogs & derivatives; therapeutic use
- From: Chinese Journal of Oncology 2005;27(3):183-185
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the effects of different treatments for hepatocellular carcinoma (HCC) with tumor thrombus in the portal vein (PVTT).
METHODSFrom Jan. 2000 to Jan. 2003, a total of 84 HCC patients with PVTT were divided into five groups based on methed of treatment: Group A (n = 9), HCC resection + PVTT removal + postoperative TACE + thymosin alpha(1); Group B (n = 20), HCC resection + PVTT removal + postoperative TACE; Group C (n = 7), HCC resection + PVTT removal; Group D (n = 38), TACE only; Group E (n = 10), conservative treatment only.
RESULTSThe rate of PVTT shrinkage or disappearance of groups A, B, C, D and E was 66.7%, 70.0%, 57.1%, 7.9% and 0, respectively with respective median survival time of 10.0, 7.0, 8.0, 5.0 and 2.0 months. The one year survival rate was 44.4%, 15.0%, 14.3%, 10.5% and 0.
CONCLUSIONResection of HCC and removal of tumor thrombus in the portal vein may have the tumor thrombus cleared in most of the patients and postoperative TACE and thymisin alpha(1) treatment may improve their survival.
